Chest
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only ArticlesAntithrombotic Therapy for Atrial Fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Section snippets
Summary of Recommendations
Note on Shaded Text: Throughout this guideline, shading is used within the summary of recommendations sections to indicate recommendations that are newly added or have been changed since the publication of Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Recommendations that remain unchanged are not shaded.
2.1.8. For patients with AF, including those with paroxysmal AF, who are at low risk of stroke (eg,
Methods
To inform our guideline development, we searched for relevant articles published since the last literature search performed for the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Specifically, for literature regarding the assessment of stroke risk in patients with AF, we searched Medline for articles published from January 1, 2005, to October 2009 using the search terms “atrial fibrillation,” “atrial
Antithrombotic Therapy for Patients With AF in General
Over the past 2 decades, numerous RCTs have investigated antithrombotic therapies to reduce the risk of thromboembolism, principally ischemic stroke, in patients with AF. In this section, we summarize the evidence and give treatment recommendations for VKA therapy, antiplatelet monotherapy (eg, aspirin), dual antiplatelet therapy with aspirin and clopidogrel, and new oral anticoagulants (eg, dabigatran) in patients with AF.
Patients With AF and Stable Coronary Artery Disease
Approximately one-third of patients with AF also have coronary artery disease.51 A recurring question is whether patients with AF for whom oral anticoagulation is indicated because of a high risk of stroke (eg, CHADS2 score of ≥ 2) and who have concomitant stable coronary artery disease should also use aspirin to prevent coronary heart disease events. In this article, we define stable coronary artery disease as the presence (or absence) of angina but no revascularization procedure (percutaneous
Antithrombotic Therapy for Patients With AF Undergoing Cardioversion
To minimize the risk of stroke and systemic embolism associated with cardioversion, therapeutic anticoagulation (eg, with adjusted-dose oral VKAs; INR 2.0-3.0) conventionally is recommended for a minimum of 3 weeks before, during, and for a minimum of 4 weeks after the procedure. For some patients with AF of documented short duration (eg, ≤ 48 h), a common practice is to cardiovert without prolonged precardioversion anticoagulation. For patients with AF duration of > 48 h or unknown duration, a
Optimal Target INR Range
For a full discussion of optimal target INR range with VKA therapy across a variety of indications, see Holbrook et al91 regarding evidence-based management of anticoagulation in this guideline. With respect to patients with AF specifically, several studies assessed oral anticoagulation at very-low INR targets or fixed low doses compared with adjusted-dose anticoagulation targeted at an INR of 2.0 to 3.0 and found that anticoagulation targeted at an INR of 2.0 to 3.0 was more effective in
Future Research
Approximately one in every three patients with AF also has coronary artery disease.51 However, the optimal approach to antithrombotic therapy in these patients is unclear. Research is needed to determine the effect of treatment with oral anticoagulation and aspirin compared with oral anticoagulation alone on patient-important outcomes of vascular death, nonfatal stroke, nonfatal MI, nonfatal major extracranial bleeding, and nonfatal systemic embolism. Research is also needed to inform
Conclusions
Stroke is a serious complication of AF, but its risk varies considerably across different groups of patients with AF. Antithrombotic prophylaxis for stroke is associated with an increased risk of bleeding. We provide recommendations for antithrombotic treatment based on net clinical benefit for patients with AF at varying levels of stroke risk. Oral anticoagulation is the optimal choice of antithrombotic therapy for patients with AF at high risk of stroke (eg, CHADS2 score ≥ 2). At lower levels
Acknowledgments
Author contributions: As Topic Editor, Dr You oversaw the development of this article, including the data analysis and subsequent development of the recommendations contained herein.
Dr You: contributed as Topic Editor.
Dr Singer: contributed as a panelist.
Dr Howard: contributed as a panelist.
Dr Lane: contributed as a panelist.
Dr Eckman: contributed as a resource consultant.
Dr Fang: contributed as a panelist.
Dr Hylek: contributed as a panelist.
Dr Schulman: contributed as a panelist.
Dr Go:
References (175)
- et al.
Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
Chest
(2012) - et al.
Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
Chest
(2012) - et al.
Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
Chest
(2012) - et al.
VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
Chest
(2012) - et al.
Patient values and preferences in decision making for antithrombotic therapy: a systematic review: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
Chest
(2012) - et al.
Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
Chest
(2012) - et al.
Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy
J Am Coll Cardiol
(2000) - et al.
Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy
J Am Coll Cardiol
(2007) - et al.
Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation—a nation wide database analysis
Atherosclerosis
(2011) - et al.
Incident stroke after discharge from the hospital with a diagnosis of atrial fibrillation
Am J Med
(2000)
Antithrombotic therapy in atrial fibrillation
Chest
Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest
Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation
Chest
Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation
J Am Coll Cardiol
A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice
J Thromb Haemost
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey
Chest
Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study
Lancet
Canadian Atrial Fibrillation Anticoagulation (CAFA) Study
J Am Coll Cardiol
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke
Lancet
Alternate-day dosing of aspirin in atrial fibrillation
Am Heart J
Primary prevention of arterial thromboembolism in the oldest old with atrial fibrillation—a randomized pilot trial comparing adjusted-dose and fixed low-dose coumadin with aspirin
Eur J Intern Med
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial
Lancet
Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study
J Am Coll Cardiol
Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
Chest
Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin
Am J Med
Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy
Am J Med
Development of a contemporary bleeding risk model for elderly warfarin recipients
Chest
Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)
Am Heart J
Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score
J Am Coll Cardiol
Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial
Lancet
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study
Circulation
Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence
Circulation
Atrial fibrillation as an independent risk factor for stroke: the Framingham Study
Stroke
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials [published correction in Arch Intern Med. 1994;154(19):2254]
Arch Intern Med
Hemorrhagic and ischemic strokes compared: stroke severity, mortality, and risk factors
Stroke
Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation
Stroke
International consensus on nomenclature and classification of atrial fibrillation; a collaborative project of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology
Europace
Thromboembolic complications in atrial fibrillation
Stroke
Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study
JAMA
Independent predictors of stroke in patients with atrial fibrillation: a systematic review
Neurology
Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data
Thromb Haemost
Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators
Stroke
Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation
Ann Intern Med
Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study
BMJ
Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study
J Stroke Cerebrovasc Dis
Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with nonrheumatic atrial fibrillation
Stroke
Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials
Arch Intern Med
Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials
Stroke
ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Circulation
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation
JAMA
Cited by (872)
Efficacy of Warfarin Therapy Guided by Pharmacogenetics: A Real-world Investigation Among Han Taiwanese
2023, Clinical TherapeuticsIdentifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning method
2023, American Heart JournalThromboplastin calibration revisited to look for possible revision of the World Health Organization recommendations
2023, Journal of Thrombosis and Haemostasis
Funding/Support: The Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines received support from the National Heart, Lung, and Blood Institute [R13 HL104758] and Bayer Schering Pharma AG. Support in the form of educational grants was also provided by Bristol-Myers Squibb; Pfizer, Inc; Canyon Pharmaceuticals; and sanofi-aventis US.
Disclaimer: American College of Chest Physician guidelines are intended for general information only, are not medical advice, and do not replace professional medical care and physician advice, which always should be sought for any medical condition. The complete disclaimer for this guideline can be accessed at http://chestjournal.chestpubs.org/content/141/2_suppl/1S.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).